Best suited for sponsors needing data-driven feasibility assessment and digital patient recruitment across multiple countries and therapeutic areas.
Best for: Studies needing enrollment acceleration and participant outreach
Editorial ranking
We compare 104 patient recruitment vendor vendors on delivery reliability, compliance readiness, data quality and value - independent profiles compiled from public sources, ranked by evidence. Currently leading: Clariness, AutoCruitment, Trialbee.
Evidence-led comparison
Best suited for sponsors needing data-driven feasibility assessment and digital patient recruitment across multiple countries and therapeutic areas.
Best for: Studies needing enrollment acceleration and participant outreach
Best suited for sponsors needing fast,scalable digital recruitment with automated pre-screening for Phase II-IV studies.
Best for: Studies needing enrollment acceleration and participant outreach
Best suited for studies needing enrollment acceleration and participant outreach. best suited for sponsors that need recruitment and retention support across global programmes.
Best for: Studies needing enrollment acceleration and participant outreach
Best suited for studies needing electronic data capture and trial workflow tools. best suited for sponsors that need irb / endpoint / patient recruitment / consulting support across global programmes.
Best for: Studies needing electronic data capture and trial workflow tools
Best suited for sponsors with complex or competitive enrollment challenges who need strategic recruitment consulting,not just technology.
Best for: Studies needing enrollment acceleration and participant outreach
Order follows the CVC evidence model. Scores appear only for vendors with verified reviews; a vendor without reviews is never given a number. Read the methodology.
This guide is for sponsors, biotech clinical operations leads, CRO project teams and site networks who need a specialist to find, pre-screen and keep participants, and who want to know which of the best patient recruitment companies for clinical trials fits their protocol. The decision usually sits with clinical operations, with input from data protection and quality.
The vendor cards above are a starting point, not a verdict. They show which vendors describe themselves as recruitment or outreach specialists and what their profiles say about phases and footprint, not how a vendor performed on a protocol like yours, how it handles UK ethics review and data protection, or what it will cost. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score.
A patient recruitment vendor generates, qualifies and hands over potential participants to investigator sites, and increasingly helps keep them in the study. Typical services include protocol-specific outreach through digital advertising, social media, patient communities and advocacy groups; online pre-screening questionnaires built from the eligibility criteria; call-centre or nurse follow-up; referral routing to the nearest open site; and retention support such as visit reminders and travel arrangements.
The boundaries matter. A recruitment vendor does not take informed consent, confirm eligibility or enrol anyone: those stay with the investigator under GCP. It is not a full-service CRO, although some CROs recruit in-house, and it is not a site network. Staffing and freelance platforms supply people rather than participants, though some appear in the table below, so check each service model.
Typical triggers are feasibility showing the site list cannot reach target alone, enrolment falling behind plan, a hard-to-reach or under-represented population, a decentralised design needing direct-to-patient reach, or a rescue study where sites have exhausted their own lists.
Ask to see the pre-screener from a comparable study. Good questionnaires translate inclusion and exclusion criteria into plain language, stop early on hard exclusions and collect no more health data than the referral needs. Ask how the logic is version-controlled against protocol amendments and how site screen-failure reasons are fed back to tighten it. An algorithmic pass is a filter, not an eligibility decision.
Much recruitment value is lost between a qualified referral and a site phone call. Look for a defined handoff: how referrals reach the site, what the site is expected to do, how capacity is checked before a campaign starts, and how status flows back from contacted to consented to randomised. Ask for a sample referral pack and the dashboard sites would see.
In the UK, adverts, social media copy, landing pages, pre-screening questionnaires and scripts form part of the ethics submission through IRAS, and changes after approval normally need an amendment before use. A capable vendor builds this into the timeline, keeps a register of approved versions, records which version each referral saw and never runs an unapproved creative variant.
Pre-screening collects special category health data, so the vendor needs a lawful basis plus an Article 9 condition, and must be clear whether it is a controller of its own patient community or your processor under an Article 28 contract. Ask for its DPIA, how contact consent is kept separate from trial consent, where data is hosted and how any transfers outside the UK are covered.
Regulators, funders and ethics committees increasingly expect trial populations to reflect the people who will use the treatment. Ask which channels reach older patients, people with lower digital engagement and ethnic minority communities, how the vendor works with community organisations, and whether it reports referral demographics, not just volume.
A participant who withdraws early can cost more than one never recruited. Check whether visit reminders, expense handling, caregiver materials and disengagement alerts are in scope, priced separately or left to sites.
ICH E6(R3) expects sponsors to oversee tasks transferred to service providers, so insist on funnel reporting by channel and site, fair attribution and audit trails. If you want a clinical trial recruitment agency UK sites will welcome, check it respects NHS research delivery processes and understands that searching NHS records is normally a care-team task, not a vendor one.
The table sets this page’s vendors side by side on the fields that matter at shortlist stage.
| Vendor | Vendor type | Service model | Geography | Study phases | Therapeutic areas |
|---|---|---|---|---|---|
| Clariness | Patient recruitment / feasibility | Patient recruitment and site support | Global (HQ: Germany) | Phase I, Phase II | Generalist |
| AutoCruitment | Digital recruitment | Digital recruitment specialist | Global (HQ: United States) | Phase I, Phase II, Phase III, Phase IV | Generalist |
| Trialbee | Recruitment and retention | Patient recruitment and retention platform | Global (HQ: United States) | Phase I, Phase II | Generalist |
| WCG | IRB / endpoint / patient recruitment / consulting | Broad support services | Global (HQ: United States) | Phase I, Phase II, Phase III, Phase IV | Generalist |
| BBK Worldwide | Recruitment and engagement | Recruitment and engagement specialist | Global (HQ: United States) | Phase I, Phase II | Generalist |
| 1nHealth | Patient recruitment | Recruitment and enrollment specialist | Global (HQ: United States) | Phase I, Phase II, Phase III, Phase IV | Generalist |
| ClinSearch (Compassionate Use) | Patient Recruitment / Retention | TBS | Global (HQ: United States) | Phase I, Phase II, Phase III | Oncology, Rare Diseases, Multi-therapeutic |
| FreelanceCRA.com | Freelancer Platform | Platform / Network | Europe (HQ: Spain) | Phase I, Phase II, Phase III, Phase IV | Multi-therapeutic |
| Klinikos | Freelancer Platform | Staffing / Resourcing | Global (HQ: United Kingdom) | Phase I, Phase II, Phase III, Phase IV | Multi-therapeutic |
| CRA Platform | Freelancer Platform | Platform / Marketplace | Global (HQ: France) | Phase I, Phase II, Phase III, Phase IV | Multi-therapeutic |
Every field comes from each vendor’s CVC profile. The dedicated recruitment specialists list global footprints with US or German headquarters, some cover early phases only, and most describe a generalist focus, so test UK reach directly. The table also includes a compassionate use specialist and freelance staffing platforms whose records sit closer to resourcing than participant outreach, so check the service model column before treating rows as like-for-like.
Clariness is a German-headquartered patient recruitment and feasibility vendor offering recruitment and site support, with a global footprint across Phase I and Phase II in generalist areas. Its stated fit is studies needing enrolment acceleration and participant outreach. Recorded strengths include the ClinLife platform and its registered patient community, feasibility analytics with site-level data, and multilingual outreach. Where to probe: results are tied to ClinLife’s reach in specific geographies and it is noted as less effective for ultra-rare diseases, so ask for evidence of UK reach.
AutoCruitment is a US-headquartered digital recruitment specialist with a global footprint, covering Phase I to Phase IV in generalist areas, and positioned for studies needing enrolment acceleration and outreach. Its record highlights automated digital recruitment, AI-powered pre-screening against eligibility criteria, pre-qualification intended to reduce screen failures, and real-time funnel analytics. Where to probe: a digital-only approach may miss people with lower digital engagement, and its pre-screening is algorithmic rather than clinical, so sites must still verify eligibility.
Trialbee runs a patient recruitment and retention platform, with a global footprint, a United States headquarters in its profile, and Phase I and Phase II coverage in generalist areas. Its stated fit is studies needing enrolment acceleration and participant outreach, with strengths in outreach scale, enrolment support and campaign execution. Where to probe: its profile notes that results depend on protocol attractiveness and market feasibility, so ask for a frank feasibility view before committing.
WCG is listed as a US-headquartered IRB, endpoint, patient recruitment and consulting organisation offering broad support services, with a global footprint across Phase I to Phase IV in generalist areas. Its profile leans towards studies needing data capture and workflow tools, with strengths in workflow control, a configurable technology stack and data visibility. Where to probe: the record notes implementation effort and process change may be needed; for UK studies, confirm how its services fit REC review through the HRA.
BBK Worldwide is a US-headquartered recruitment and engagement specialist with a global footprint and Phase I and Phase II coverage in generalist areas, aimed at studies needing enrolment acceleration and outreach. Recorded strengths include a patient-centric methodology with retention programmes, real-time enrolment analytics with predictive modelling, and multi-channel campaigns spanning digital, community and site-level activity. Where to probe: its consultancy model is noted as costing more than platform-only options, and results vary by therapeutic area and protocol complexity.
1nHealth is a US-headquartered recruitment and enrolment specialist with a global footprint, covering Phase I to Phase IV in generalist areas for studies needing enrolment acceleration and outreach. Its record cites AI-powered patient matching with predictive enrolment modelling, digital-first programmatic and social campaigns, decentralised trial recruitment and real-time enrolment dashboards. Where to probe: effectiveness depends on protocol attractiveness and therapeutic area density, and its track record in ultra-niche rare disease populations is noted as limited.
ClinSearch (Compassionate Use) is a US-headquartered patient recruitment and retention vendor with a global footprint, covering Phase I to Phase III in oncology, rare diseases and multi-therapeutic work at small and medium scale. Its stated fit is pharma companies setting up compassionate use or expanded access programmes, with strengths in patient access and regulatory navigation. Where to probe: the record describes a niche expanded access focus and limited trial services, so it suits access programmes rather than mainstream trial recruitment.
FreelanceCRA.com is a Spanish-headquartered freelancer network with a European footprint, covering Phase I to Phase IV in multi-therapeutic studies from small to large. Its profile fits sponsors needing senior freelance CRAs, European multi-site monitoring, regulatory start-up support or gap cover for CRA teams, with strengths in a multilingual senior CRA pool and pan-European coverage. Where to probe: it is not a full-service CRO and works mainly in monitoring and regulatory roles, so it supplies monitoring and regulatory staff rather than finding participants.
Klinikos is a UK-headquartered freelancer platform offering staffing and resourcing, with a global footprint and Phase I to Phase IV coverage in multi-therapeutic studies from small to large. Its profile fits UK-based CRA staffing, field monitoring, regulatory and project management expertise, and flexible trial staffing. Recorded strengths include a UK headquarters with global reach, its field-based focus and a flexible resourcing model. Where to probe: it is a staffing provider rather than a technology platform, with a smaller network than generalist agencies.
CRA Platform is a freelancer marketplace headquartered in France with a global footprint and Phase I to Phase IV coverage in multi-therapeutic studies from small to large. Its profile fits freelance CRA sourcing and senior CRA, CTM and project manager placement, with strengths in digital matching, senior-level talent and quick matching. Where to probe: the record notes it is a relatively new platform with variable vetting depth and no full-service capability, so ask how candidates are checked.
Recruitment is usually bought in a few recognisable ways. A fixed or milestone engagement pays for set-up, creative, ethics submission support, pre-screener build and a defined outreach period, with media spend often passed through at cost. A performance-based engagement pays per qualified referral, consented participant or randomised participant. Hybrids combine a set-up fee with performance payments, and retention is often a separate workstream.
Cost is driven by population rarity and geography, pre-screener complexity, countries and languages, the volume of creative needing ethics approval, media channels, nurse or call-centre follow-up and campaign length. Paying per referral rewards volume and can flood sites with poor matches; paying per randomisation aligns incentives but the vendor prices in site risk it cannot control. Fixed fees give budget certainty but weaker incentives. Whatever the model, define every funnel stage in the contract, agree attribution rules up front, and check that any payment linked to referrals has been disclosed to the ethics committee where required.
Use the vendor directory to filter recruitment and retention specialists by phase, geography and focus, then set your candidates side by side on the compare page. If you need a patient recruitment CRO UK sites can work with, look closely at headquarters, footprint and service model. Send a structured request through our sponsor RFP so every vendor answers the same questions. If you have worked with any of these vendors, please write a review: first-hand accounts help other sponsors judge how recruitment vendors perform in practice.
Due diligence
Leading vendors in this category combine documented trial experience, therapeutic expertise, robust quality systems, and transparent pricing. Clinical Vendor Compare tracks verified vendor data — experience metrics, review scores, and evidence notes — so sponsors can compare candidates side by side.
Rankings are computed from verified evidence in the CVC vendor dataset: criterion-level scores, platform review scores, public review coverage, and studies managed. No vendor can pay to change a rank; sponsored placements are labelled separately.
The CVC dataset covers hundreds of verified clinical vendors across CRO, technology, and specialist-service categories, each with structured criteria, evidence notes, and source links. Use the compare view on this page to filter by your study needs.
No. Comparison pages, shortlists, and vendor profiles are free for sponsors. Vendors can claim and enhance their profiles, but review data and rankings remain independent.
Start with your protocol and target population, then test each agency on UK reach, its pre-screening logic, how referrals are handed to NHS and independent sites, and its approach to ethics approval of materials and UK GDPR. Ask for a sample referral pack and funnel report from a comparable study, and confirm who will do the work day to day. A clinical trial recruitment agency UK sites trust will also respect local capacity.
Generally yes. Adverts, social media posts, landing pages, pre-screening questionnaires, call scripts and participant-facing retention materials are usually reviewed by the research ethics committee as part of the IRAS submission. New or changed materials after approval normally go through the amendment process before they are used. Your vendor should keep a register of approved versions and never run unapproved variants.
Not directly. Searching NHS records to identify potential participants is normally carried out by the patient’s direct care team, or under a specific legal approval route for access without consent. Recruitment vendors typically reach patients through advertising, patient communities and advocacy groups, then refer interested people to sites, where the research team confirms eligibility and takes consent.
Pre-screening answers are health data, so the vendor needs a lawful basis plus an Article 9 condition, often explicit consent for this stage. The contract should be clear on controller and processor roles, a DPIA should cover the activity, and any transfers outside the UK need a valid mechanism. Consent to be contacted is separate from informed consent to join the trial.
Per-referral pricing is simple but can reward volume over quality and overload sites. Paying per randomised patient aligns incentives more closely, but the vendor carries site risk and prices it in. Many sponsors use a hybrid: a set-up fee for creative, ethics support and pre-screening, then performance payments at agreed funnel stages. Define each stage precisely in the contract.
No. A buyer searching for a patient recruitment CRO UK teams can use usually needs a specialist that finds and refers participants, not one that runs monitoring, data management and the wider study. Some full-service CROs offer recruitment in-house, and some recruitment specialists offer site support, but consent, eligibility confirmation and enrolment always stay with the investigator and site.
Look for channels beyond social media, such as community organisations, patient advocacy groups, translated and culturally adapted materials, and support with travel or time off. Ask for demographic reporting on referrals and randomisations, not just totals, and agree in advance what the vendor will do if the funnel does not reflect the population the study is meant to represent.
The vendor passes the referral to a participating site, ideally through a tracked handoff that records when the site makes contact. The site team then discusses the study, confirms eligibility through its own screening, and takes informed consent. Good vendors receive status updates back so they can report the full funnel and use screen-failure reasons to refine targeting.